Individuals with asthma and chronic obstructive pulmonary disease (COPD) were more vulnerable than healthy controls to ...

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

Peter Shadday becomes CEO as company is moving into a commercial-stage company, increasingly focused on U.S. market ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Respiratory Care Devices - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global market size for ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

The respiratory care devices market growth is propelled by the increasing incidence of respiratory disorders such as asthma, COPD, and sleep apnea, primarily due to factors like environmental ...

The respiratory care devices market growth is propelled by the increasing incidence of respiratory disorders such as asthma, COPD, and sleep apnea, primarily due to factors like environmental ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...